These findings are significant, especially in the era of targeted therapies, with menin inhibitors being brought to the frontline treatment of NPM1-mutated AML [105], which could in turn be used in treating MS, only if the molecular architecture of MS and AML is clarified in all patients. The gene discussed is NPM1; the disease is myeloid sarcoma.